BiotechTube

WT-gag-TCR modified T cells + α/6-gag-TCR modified T cells

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV Infections

Conditions

HIV Infections

Trial Timeline

Nov 1, 2009 → Jan 1, 2014

NCT ID
NCT00991224

About WT-gag-TCR modified T cells + α/6-gag-TCR modified T cells

WT-gag-TCR modified T cells + α/6-gag-TCR modified T cells is a phase 1 stage product being developed by Adaptimmune Therapeutics for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00991224. Target conditions include HIV Infections.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00991224Phase 1Completed

Competing Products

20 competing products in HIV Infections

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
25
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
VN-0200Daiichi SankyoPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
85
MicafunginAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 1
33
Micafungin + PlaceboAstellas PharmaPhase 3
77
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
GW810781ShionogiPhase 2
52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
CefiderocolShionogiPhase 2
52

Other Products from Adaptimmune Therapeutics

Treatment with NY-ESO-1c259-modified T cellsPhase 1/2
33
NYESO-1c259 T cellsPhase 1/2
33
GSK3901961 + GSK3845097 + GSK4427296 + Cyclophosphamide + FludarabinePhase 1
25
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶TPhase 1
25
GSK3901961 + Cyclophosphamide + FludarabinePhase 1
25